Bethyl Laboratories
Mouse anti-TIGIT Monoclonal Antibody [BLGM174]New
Primary
Catalog #A501-174
TargetTIGIT
HostMouse
CloneBLGM174
ReactivityHuman
ApplicationIHC
Image 1 of 1
local_shipping
This item has an estimated lead time of two weeks.
Product Description
TIGIT is a member of the PVR (poliovirus receptor) family of immunoglobin proteins and is expressed on several classes of T cells including follicular B helper T cells (TFH). TIGIT has been shown to bind PVR with high affinity; this binding is thought to assist interactions between TFH and dendritic cells to regulate T cell dependent B cell responses. [taken from NCBI Entrez Gene (Gene ID: 201633)].
Specifications
Clonality
Monoclonal
Clone
BLGM174
Host
Mouse
Isotype
IgG2a, kappa
Reactivity
Human
Format
Whole IgG
Conjugate Type
Unconjugated
Purity
Purified
Target Identity
TargetTIGIT
Antigen Species
Human
Gene ID201633
Gene Symbol
TIGIT
Gene Name
T-cell immunoreceptor with Ig and ITIM domains
Uniprot IDQ495A1
Protein Name
T-cell immunoreceptor with Ig and ITIM domains
Alternate Names
T-cell immunoreceptor with Ig and ITIM domains • V-set and immunoglobulin domain containing 9 • V-set and immunoglobulin domain-containing protein 9 • V-set and transmembrane domain containing 3 • V-set and transmembrane domain-containing protein 3 • VSIG9 • VSIG9, VSTM3 • VSTM3 • Washington University cell adhesion molecule • WUCAM
Product Information
Applications
IHC
Buffer
Tris-buffered Saline with 1% BSA and <0.1% Sodium Azide
Storage Conditions
2 - 8 °C
Physical State
Liquid
Shelf Life
1 year from date of receipt
Country of Origin
USA
Applications
Immunohistochemistry (IHC)1:50 to 1:200
Documents
Product DatasheetPDF · A501-174 · Lot 1 (current lot)Open
Product DatasheetPDF · A501-174 · Lot 1 (current lot)Open
Safety Data SheetPDF · A501-174Open
Services
Antibody Conjugation
Antibody and conjugate formats developed together, built to your specification.
Request CustomizationCustom Monoclonal Antibody Discovery Services
Full custom monoclonal development, from immunization through validation.
Explore Monoclonal DevelopmentVHH Discovery
Single-domain antibodies for structurally difficult targets a conventional monoclonal can't reach.
Explore VHH DiscoveryResources
1



